DNA Chip Research Inc.

As of March 31, 2024, DNA Chip Research Inc. has 6.76M shares outstanding.

These figures are as of March 31, 2024. The price-to-sales ratio is 20.71, and the price-to-book ratio stands at -45.62.

As of March 31, 2024, DNA Chip Research Inc. maintains a current ratio of 3.24, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2024. Return on assets (ROA) is negative at -26.79, reflecting losses generated across the asset base. Inventory turnover of 9.84 indicates how many times DNA Chip Research Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on June 18, 2025, DNA Chip Research Inc.'s stock has gained approximately 16.54% over the past 52 weeks. The 50-day moving average sits at 49.11M, while the 200-day moving average is 12.28M.

Over the twelve months ended March 31, 2024, DNA Chip Research Inc. posted a gross margin of 13.53, reflecting its pricing power and cost economics. The operating margin of -52.65 and net profit margin of -50.62 provide insight into operational efficiency.

DNA Chip Research Inc.'s most recent stock split took place on September 26, 2013 with a 1:100 split ratio.

As of March 31, 2024, DNA Chip Research Inc. has an Altman Z-Score of 22.69, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.